421PEGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC). (22nd November 2017) - Akamatsu, H; Delmonte, A; John, T; Su, W-C; Lee, J-S; Chang, G-C; Huang, X; Jenkins, S; Dearden, S; Wu, Y-L